Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06043531 · ClinicalTrials.gov registry record · NA
Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT06043531 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 19 participants.
The verdict
NCT06043531, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. TMAO is an attractive therapeutic target to improve vascular health and diastolic function toward preventing CVD in LT patients. Therefore, the purpose of this study is to better understand the role of TMAO in cardiovascular dysfunction patients with chronic kidney disease.
Interventions
- OTHER Experimental: EVOO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2024-10-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06043531
The ClinicalTrials.gov registry entry for NCT06043531 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Experimental: EVOO is the first listed.
NCT06043531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06043531 about?
NCT06043531 is a clinical study titled "Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients". Despite medical and surgical advances, long-term survival in liver transplant (LT) recipients is compromised by an increased risk of cardiovascular disease (CVD) after transplant, the mechanisms of which are still not fully understood. TMAO is an attractive therapeutic target to improve vascular hea...
What is the current status of trial NCT06043531?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2024-01-18. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT06043531?
The interventions under investigation include: Experimental: EVOO (OTHER).
Who is sponsoring clinical trial NCT06043531?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.